1 / 7

Treatment according to ALT and LSM

Treatment according to ALT and LSM. < 8 kPa. > 8 kPa. EASL 2011 - D’après Leroy V et al., abstract 128, actualisé. Study Design. Year 2. Randomisation 1:1. • OLT recipient for CHB infection • ≥ 12 weeks of prophylactic therapy including HBIG • HBV DNA negative

hilda-horne
Download Presentation

Treatment according to ALT and LSM

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Treatmentaccording to ALT and LSM < 8 kPa > 8 kPa EASL 2011 - D’après Leroy V et al., abstract 128, actualisé.

  2. Study Design Year 2 Randomisation 1:1 • OLT recipient for CHB infection • ≥ 12 weeks of prophylactictherapyincluding HBIG • HBV DNA negative • HBsAgnegative FTC/TDF FTC/TDF+HBIGN = 40 FTC/TDF+HBIG Enrollment Week 24 Week 96 FTC + TDF isgiven as a fixed-dosecombinationtablet (Truvada) taken once daily. EASL 2011 - D’aprèsTeperman L et al., abstract 574, actualisé.

  3. Virologicalresponse* by baselineviremia 99% 97% DNA ≤ 5 log 63% DNA 5-8 log DNA ≥ 8 log P < 0,0001 • 75 68 26 9 4 3 2 • 171 161 96 48 25 12 5 • 35 34 30 22 17 10 7 Patients stillatrisk * Kaplan-Meierestimates EASL 2011 - D’aprèsLampertico P et al., abstract 731, actualisé.

  4. Conclusion Entecavirtreatmentpreventsdisease progression and increased the survival of patients with HBV-ACLF. The established TPPM scorring system offerssuperiorpredictory value in bothspecificity and sensitivityfor HBV-ACLF patients whencomparedwith MELD Multivariatelogisticregressionanalysis of independentriskfactors for mortality in patients with HBV-ACLF Entecavirtreatment NA free Fig. 1-month and 3-month survival rates of patients treatedwithentecavirwere 72,58% and 61,29%, respectivelywhilethose of patients not treatedwithentecavirwere 53,23% and 45,97%, respectivelly. (1-month survival rates p = 0,002; 3 monthsurvival rates p = 0,022). Comparison of curves, (p = 0,0054, HR = 0,596, 95% CI 0,413-0,861) B: coefficient for the constant; SE: standard error; Wald: chi-square value; EXP(B): exponentiation of the B coefficient. EASL 2011 - D’aprèsNing Q et al., abstract 742, actualisé.

  5. Results: cumulative incidence of HCC 11,1% Persistentlydetectable HBV DNA Seroclearance of HBV DNA 1,5% EASL 2011 - D’après Liu J et al., abstract 68, actualisé.

  6. IL28B genotypeisassociatedwithHBeAgseroconversionthrough LTFU in all HBV genotypes 100 (49%) patients achievedHBeAgseroconversionthrough LTFU Overall p = 0,007 AA AG/GG EASL 2011 - D’après Sonneveld MJ et al., abstract 71, actualisé.

  7. IL28B genotypeisindependentlyassociatedwithHBsAgseroclearancethroughlong-termfollow-up Hazard ratio for AA versus AG/GG:3,47 (1,04-13,48) • 18 (9%) achievedHBsAgloss • Medianfollow-upuntilresponse or censoring: • 173 (IQR 108 – 356) weeks • HBsAglosssignificantlyassociatedwith HBV genotype (A versus non-A) AA genotype AG/GG genotype EASL 2011 - D’après Sonneveld MJ et al., abstract 71, actualisé.

More Related